Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice-Reference-Cited by-同舟云学术

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

Published:2019-05-04 Issue:5 Volume:18 Page:415-425
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Cantini Fabrizio¹,Niccoli Laura¹,Capone Alessandro²,Petrone Linda³,Goletti Delia³^ORCID

Affiliation:

1. Department of Rheumatology, Hospital of Prato, Prato, Italy

2. Clinical Department, National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy

3. Translational Research Unit, Department of Epidemiology and Preclinical Research, “L. Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2019.1612872

Reference110 articles.

1. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

2. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

3. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis